| pubmed-article:21723596 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21723596 | lifeskim:mentions | umls-concept:C0302592 | lld:lifeskim |
| pubmed-article:21723596 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:21723596 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:21723596 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:21723596 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:21723596 | lifeskim:mentions | umls-concept:C0205132 | lld:lifeskim |
| pubmed-article:21723596 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21723596 | pubmed:dateCreated | 2011-9-12 | lld:pubmed |
| pubmed-article:21723596 | pubmed:abstractText | The aim of the study was to determine the response rate and response duration of cervical cancer previously treated by cisplatin (with or without radiation) to a combination of docetaxel and gemcitabine. Secondary endpoints were assessment of toxicity and quality of life (QoL) of patients receiving the treatment. | lld:pubmed |
| pubmed-article:21723596 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21723596 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21723596 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21723596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21723596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21723596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21723596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21723596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21723596 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21723596 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:21723596 | pubmed:issn | 1095-6859 | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:PaulJJ | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:McMahonTT | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:SymondsR PRP | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:ChanSS | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:RakBB | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:DavidsonS ESE | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:RiceS WSW | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:HardenSS | lld:pubmed |
| pubmed-article:21723596 | pubmed:author | pubmed-author:Scottish... | lld:pubmed |
| pubmed-article:21723596 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21723596 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21723596 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:21723596 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21723596 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21723596 | pubmed:pagination | 105-9 | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:meshHeading | pubmed-meshheading:21723596... | lld:pubmed |
| pubmed-article:21723596 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21723596 | pubmed:articleTitle | SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. | lld:pubmed |
| pubmed-article:21723596 | pubmed:affiliation | University of Leicester, Department of Cancer Studies & Molecular Medicine, Leicester, UK. rps8@le.ac.uk | lld:pubmed |
| pubmed-article:21723596 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21723596 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21723596 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21723596 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
